Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMM-1-104 by Immuneering for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
IMM-1-104 by Immuneering for Lung Adenocarcinoma: Likelihood of Approval
IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
IMM-1-104 by Immuneering for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
IMM-1-104 by Immuneering for Non-Small Cell Lung Cancer: Likelihood of Approval
IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Immuneering's IMM-1-104?
IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer. According to Globaldata,...